The results of therapeutic plasma exchange in patients with severe hyperthyroidism: A retrospective multicenter study

KEKLİK M., KAYNAR L., Yilmaz M., Sivgin S., Solmaz M., Pala C., ...More

Transfusion and Apheresis Science, vol.48, no.3, pp.327-330, 2013 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1016/j.transci.2013.04.010
  • Journal Name: Transfusion and Apheresis Science
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.327-330
  • Keywords: Hyperthyroidism, Therapeutic plasma exchange
  • Istanbul Medipol University Affiliated: No


Hyperthyroidism characterized by elevated serum levels of circulating thyroid hormones. The aim of hyperthyroidism treatment is to achieve a euthyroid state as soon as possible and to maintain euthyroid status. However, drug withdrawal and utilization of alternative therapies are needed in cases in which leucopenia or impairment in liver functions is observed during medical therapy. In the present study, we aimed to present our cases which underwent therapeutic plasma exchange (TPE) due to severe hyperthyroidism. The results of 22 patients who underwent therapeutic plasma exchange due to hyperthyroidism in Apheresis Units of Erciyes University and Gaziantep University, between 2006 and 2012, were retrospectively reviewed. These cases had severe thyrotoxic values despite anti-thyroid drug use. After TPE, we observed a significant decrease in free thyroxin (FT4) (p<. 0.001) and free triiodotyhronin (FT3) (p<. 0.004) levels. There was statistically significant increase in the mean values of TSH levels after TPE (p<. 0.001).Clinical improvement was achieved in hyperthyroidism by TPE in 20 cases (91%). Both FT3 and FT4 levels remained above the normal limits in two of 22 patients. TPE should be considered as an effective and safe therapeutic option to achieve euthyroid state before surgery or radioactive iodine treatment. TPE is a useful option in cases with severe hyperthyroidism unresponsive to anti-thyroid agents and in those with clinical manifestations of cardiac failure and in patients with severe adverse events during anti-thyroid therapy. © 2013 Elsevier Ltd.